ImmusanT: Having their cake
ImmusanT's vaccine could allow celiac patients to eat normally
ImmusanT Inc. is developing what could be the first treatment for celiac disease that allows patients to eat a normal diet. The company's Nexvax2 vaccine seeks to reprogram CD4+ T cells to induce gluten tolerance.
The biotech also is developing a blood-based companion diagnostic. Both programs were acquired from Nexpep Pty. Ltd., which is now a shell company.
Celiac disease is an immune-mediated disorder triggered by consumption of foods containing gluten, which is broken into immunogenic peptides that are allowed to pass through the intestinal epithelium.
The peptides are